Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
Compose a Response to This Article
Other responses
No responses have been published for this article.